Venclexta/rituximab (venetoclax/rituximab)

pCPA File Number: 21136

Negotiation Status:

Concluded with an LOI

Indication(s):

Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible

Sponsor/Manufacturer:

AbbVie Corporation

CADTH Project Number:

pCODR 10162

pCPA Engagement Letter Issued:

2019-06-26

Negotiation Process Concluded:

2019-10-28